Vigil Neuroscience (VIGL) Stock Price, News & Analysis

Company Overview

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $1.66 to $1.81
• 50-Day Range: $1.68 to $3.03
• 52-Week Range: $1.49 to $6.06
• Volume: 131,587 shs
• Average Volume: 468,106 shs
• Market Capitalization: $82.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.25
• Consensus Rating: Buy

Vigil Neuroscience Stock Analysis - MarketRank™

Vigil Neuroscience scored higher than 79% of companies evaluated by MarketBeat, and ranked 205th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vigil Neuroscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vigil Neuroscience has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.07) to ($2.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vigil Neuroscience is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vigil Neuroscience is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vigil Neuroscience has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.85% of the float of Vigil Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Vigil Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vigil Neuroscience has recently decreased by 25.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vigil Neuroscience does not currently pay a dividend.

Dividend Growth

Vigil Neuroscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.85% of the float of Vigil Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Vigil Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vigil Neuroscience has recently decreased by 25.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.69

News Sentiment

Vigil Neuroscience has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Vigil Neuroscience this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for VIGL on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

4 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIGL Stock Analysis - Frequently Asked Questions

How have VIGL shares performed this year?

Vigil Neuroscience's stock was trading at $1.70 at the beginning of 2025. Since then, VIGL stock has increased by 4.1% and is now trading at $1.77.
View the best growth stocks for 2025 here.

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its quarterly earnings data on Thursday, March, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.08.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vigil Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 4/02/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIGL
• CIK: 1827087
• Web: vigilneuro.com
• Phone: 857-254-4445
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.25
• High Stock Price Target: $22.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +818.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-82,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -83.89%
• Return on Assets: -65.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.72
• Quick Ratio: 3.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.24 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 46,672,000
• Free Float: 27,377,000
• Market Cap: $82.61 million
• Optionable: Not Optionable
• Beta: 1.82